bevacizumab,adagrasib,tucatinib,trastuzumab deruxtecan,regorafenib,encorafenib,cetuximab,ruxolitinib,sotorasib,trifluridine tipiracil,panitumumab,fruquintinib,pertuzumab
roche,mirati therapeutics,daiichi sankyo,astrazeneca,incyte,otsuka,pfizer,bayer,eli lilly,novartis,amgen,hutchmed,seagen,taiho pharma
[]
. presents a very nice summary of treatment options for conventionally refractory, mss mcrc at #gi23, describing sunlight as a new soc combining tas-102 &amp; bev #crcsm 
Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own.